Lenvatinib plus immunotherapy with TACE versus standard TACE
Part of Cancer, Digestive system clinical trials.
This study compares a stronger treatment plan (lenvatinib plus sintilimab plus TACE) against a standard plan (lenvatinib plus TACE) for advanced liver cancer. It aims to see which plan works better to control tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (HCC), confirmed by biopsy/samples or by a clear clinical diagnosis
- Your cancer can be treated with TACE and you have at least one measurable liver tumor seen on scans
- Your liver function is in the Child-Pugh A or B range
- You feel able to do daily activities most of the time (ECOG 0–1) and are expected to live at least 3 months
- Your liver cancer can’t involve blocked portal veins in a way that blocks both sides (unless special collateral vessels are present)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for liver cancer (HCC) that has stopped responding to TACE. One group gets lenvatinib (a targeted therapy pill) plus SIRT (internal radiation beads placed in the liver), and the other gets lenvatinib alone. The goal is to see which combination works better.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
This Phase 3 trial compares lenvatinib plus implanted radiation seeds versus lenvatinib alone in people with liver cancer that no longer responds to TACE. It aims to improve how long patients can control the cancer inside the liver.
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a liver-directed treatment (DEB-TACE) with or without another liver treatment (HAIC) for people with large liver cancer (over 7 cm) that has spread into the main blood vessel of the liver. The goal is to see if adding HAIC helps shrink the cancer more effectively.
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This trial tests a combination of a focused radiation beam (SBRT) plus a pill that helps stop tumor blood vessel growth (lenvatinib) and a procedure that blocks blood flow to the tumor (TACE) for people with advanced liver cancer that has not yet spread outside the liver. The goal is to see if this triple therapy can improve outcomes without prior treatment.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.